K-FLAM

Quick links

Choose a section

Quick links to important sections

Advertisements

K-FLAM

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of K-FLAM

Quick Facts

Property Description
Active Ingredients Diclofenac and Paracetamol (Acetaminophen)
Form Tablet (Oral Dosage Form)
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID) and Analgesic/Antipyretic Combination
General Purpose Symptomatic relief of pain, inflammation, and fever
Origin Synthetic

What Type of Medicine is K-FLAM?

K-FLAM is defined as a fixed-dose combination drug, which integrates two distinct active ingredients into a single oral dosage form. Pharmacologically, it is classified as a synergistic blend of a Non-Steroidal Anti-Inflammatory Drug (NSAID) and an Analgesic/Antipyretic. This classification recognizes its utility for managing acute discomfort. The dual-action type distinguishes it from monotherapy agents, allowing it to address both inflammation and central pain perception. Both constituent compounds are synthetic in origin, ensuring chemical consistency.

What is the Composition and Form of K-FLAM?

The formulation includes two key active ingredients: Diclofenac (frequently used as the rapid-dissolving Potassium salt) and Paracetamol, which is also known as Acetaminophen. Diclofenac acts as the NSAID component, recognized for its anti-inflammatory effects, while Paracetamol serves as the widely used pain and fever reducer. The combination of Diclofenac and Paracetamol is clinically recognized for providing enhanced analgesia compared to either agent administered alone. These synthetic compounds are formulated together as a solid tablet, providing a convenient and stable oral dosage form for ingestion.

What is the General Purpose of the K-FLAM Combination?

The general purpose of this specific combination drug is the integrated management of acute symptoms, typically utilized in scenarios like intense muscular discomfort or symptoms accompanying common infectious illnesses. The strategic combination of Diclofenac and Paracetamol is intended for the simultaneous symptomatic treatment of pain, inflammation, and elevated body temperature. This integrated approach, which offers comprehensive pain relief, effective inflammation reduction, and reliable fever reduction, is designed for adults seeking relief from symptoms where a strong anti-inflammatory effect is required alongside central pain modulation.

Regulatory References

  1. MedlinePlus Drug Information
Advertisements

What side effects are possible with K-FLAM?

Possible Side Effects and Safety Information

The safety profile for K-FLAM, a combination of Diclofenac and Paracetamol, is structured by government regulatory documents based on the known risks of its two active components. Adverse reactions are grouped by System-Organ Class (SOC) and assigned frequency classifications to communicate the risk profile.

Officially documented side effects are categorized into several SOCs. Gastrointestinal Disorders (e.g., nausea, abdominal pain, diarrhea) are classified as common. Other affected systems include the Nervous System (headache, dizziness), Hepatobiliary System (elevated liver enzymes), and Skin and Subcutaneous Tissue (rash).

Classification Examples of Officially Documented Adverse Reactions
Common Nausea, vomiting, abdominal pain, dyspepsia, headache, elevated liver enzymes.
Rare/Very Rare Gastrointestinal haemorrhage, anaphylactic reactions, severe hepatic failure, serious skin reactions (SJS, TEN).

The most serious adverse reactions listed in regulatory texts include Gastrointestinal Bleeding, Ulceration, and Perforation, which carry a risk of fatal outcomes. The official labeling also notes the risk of Cardiovascular Thrombotic Events such as myocardial infarction and stroke, primarily associated with the NSAID component.

Official safety constraints note that risk can be influenced by exposure; the risk of arterial thrombotic events may increase with higher doses and longer duration of exposure. Furthermore, safety documents mandate specific constraints for use in certain populations: the medicine is contraindicated in patients with established congestive heart failure (NYHA Class II-IV) and severe hepatic or renal impairment, reflecting high-level regulatory limitations.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes the K-FLAM overdose profile based on the toxicities of its two components: Diclofenac and Paracetamol.

Overdose Manifestations and Severe Outcomes

Category Documented Manifestations and Risks
Component Toxicity Overdose may present with non-specific initial symptoms such as nausea, vomiting, headache, or dizziness. Severity is not correlated with early symptoms.
Severe Outcomes The Paracetamol component presents a primary risk of severe hepatic injury (liver failure), which is often delayed and can be fatal. The Diclofenac component carries the risk of serious gastrointestinal bleeding, ulceration, or perforation, and acute renal damage.

Emergency Actions Mandated by Regulators

Immediate medical attention must be sought for any suspected overdose. This action is mandatory even if the patient feels well, due to the critical risk of developing delayed, severe liver damage from the Paracetamol component. Referral to a hospital is essential for immediate medical attention and continuous monitoring.

Management involves symptomatic and supportive measures. The antidote Acetylcysteine is specifically used to counteract Paracetamol toxicity. For the Diclofenac component, no specific antidote is known. Procedures such as activated charcoal and gastric lavage may be considered, and monitoring of hepatic and renal function is required.

Advertisements

Therapeutic Uses of K-FLAM

The combination is applied across domains where additional symptomatic support is needed for symptoms related to physical discomfort, inflammation, and systemic imbalance. It is utilized in settings where symptoms create noticeable interference with a patient's functional stability.


Musculoskeletal Pain and Inflammatory Conditions

This domain is considered relevant for managing symptoms related to inflammatory or irritative states and physical discomfort in the body’s structural components, including joints, muscles, and soft tissues. It is commonly used across conditions characterized by periods of heightened symptoms, such as the episodic manifestations of osteoarthritis and rheumatoid arthritis, to ease joint stiffness and discomfort. The supportive relief generally provides support that helps ease the overall symptom burden, which contributes to improved day-to-day comfort during periods of heightened symptoms.


Acute, Localized Discomfort and Systemic Symptoms

K-FLAM is applied in scenarios where short-term symptomatic assistance is needed for acute painful episodes. This includes addressing symptoms related to dental pain after procedures, certain headaches, and discomfort associated with menstrual cramps. The medication is also commonly used to help with symptom clusters that may appear suddenly, addressing symptoms related to systemic imbalance and physical discomfort, such as generalized aches and febrile states. This focused symptomatic relief helps patients cope more steadily with difficult, temporary episodes of heightened discomfort.


Quick Fact: Relevant for Acute Symptom Management
Symptom Cluster Addressed Pain, Inflammation, and Elevated Body Temperature
Common Clinical Contexts Musculoskeletal flare-ups, post-procedure discomfort, acute injuries
Core Patient Benefit Provides support that helps ease the overall symptom load
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use K-FLAM?

Eligibility for K-FLAM is defined by regulatory documents based on patient health status and age, primarily due to the established risks associated with its Diclofenac (NSAID) component.

Contraindicated Populations (Must Not Use)

Classification Formal Exclusion Criteria
Allergy/Sensitivity Known hypersensitivity to Diclofenac, Paracetamol, or a history of allergic reactions (e.g., asthma, urticaria) after taking Aspirin or other NSAIDs (Source 2.2).
Cardiovascular Disease Established congestive heart failure (NYHA Class II-IV), ischaemic heart disease, cerebrovascular disease, or post-Coronary Artery Bypass Graft (CABG) surgery (Source 1.2, 2.2).
Organ Dysfunction Severe hepato-cellular insufficiency (severe liver disease) or severe renal insufficiency (severe kidney disease) (Source 3.1).
Gastrointestinal Risk Active peptic ulceration, gastrointestinal bleeding, or perforation (Source 1.2).

Age and Pregnancy Restrictions

K-FLAM is officially intended for use in the adult population. Its use is formally contraindicated in children and adolescents below a specific age (typically under 14 or 15 years, depending on the regulatory region) (Source 3.1). The medicine is contraindicated in women starting at 30 weeks gestation and later (third trimester of pregnancy) (Source 4.4). For older adults, its use requires caution due to a heightened risk of adverse gastrointestinal and renal events (Source 2.1).

Conditional Use (Caution Required)

Patients with certain pre-existing conditions, such as hypertension, mild-to-moderate renal or hepatic impairment, or a history of GI ulceration, may only use K-FLAM under medical supervision and with careful monitoring (Source 2.3).

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes specific interaction patterns for K-FLAM, which contains Diclofenac and Paracetamol.

Contraindicated Combinations

Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including other Diclofenac formulations or Ibuprofen, is restricted due to a documented increased risk of serious gastrointestinal events. The combination is strictly prohibited with other Paracetamol/Acetaminophen-containing products to avoid exceeding the maximum daily dose, a constraint related to the risk of severe liver toxicity. Use is also contraindicated for managing perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Pharmacodynamic and Exposure Interactions

The Diclofenac component increases the risk of bleeding when combined with Anticoagulants (like Warfarin) and Anti-Platelet Agents, a documented pharmacodynamic interaction. K-FLAM may also reduce the effect of certain Diuretics and Antihypertensives and may increase the nephrotoxicity risk of Immunosuppressants such as Ciclosporin. Official documents note that Diclofenac co-administration may increase the plasma concentrations of Lithium, Digoxin, and Methotrexate. The strong CYP2C9 inhibitor Voriconazole is documented to significantly increase Diclofenac exposure (AUC and C max).

Substance and Timing Restrictions

Chronic consumption of three or more alcoholic drinks per day is a documented condition that increases the risk of Paracetamol hepatotoxicity. Furthermore, a timing rule applies to Mifepristone; NSAIDs should not be used for 8 to 12 days following its administration.

Advertisements

Mechanism of Action

How K-FLAM Works

K-FLAM is a combination drug that acts within two primary, distinct mechanistic domains to modulate afferent nociceptive and thermoregulatory signaling cascades.


Core Mechanism: Modulation of the Eicosanoid Pathway

This core mechanism is driven by Diclofenac, which primarily targets the cyclooxygenase (COX) enzymes. These enzymes are critical for converting arachidonic acid into pro-inflammatory mediators, known as prostaglandins. By inhibiting both COX-1 and COX-2 enzymes, K-FLAM limits the synthesis of these signaling molecules, thereby initiating a cascade that leads to the limitation of pro-inflammatory mediator production in peripheral tissues and modulation of nociceptive signaling.


Central Influence on Nociception and Thermoregulation

The second mechanistic domain involves Paracetamol, which exerts its influence predominantly within the Central Nervous System (CNS). This activity is believed to modulate afferent nociceptive signaling and influence the activity of the body's hypothalamic thermoregulatory center. This central action influences the threshold for central nociceptive perception and promotes the resetting of the hypothalamic thermoregulatory set-point, influencing the total mechanistic profile of the combination by regulating neural pathways.

Advertisements

Dosage and Administration Information

How K-FLAM is Used

The official usage of K-FLAM is governed by the administration parameters detailed in official documentation. The medicine is provided as an oral tablet for ingestion, which defines the only approved route of administration.

Standard Administration and Dosing

The medicine is administered in a daily regimen using divided doses. The standardized single quantity for adults is one tablet (Diclofenac 50 mg / Paracetamol 500 mg), with a typical frequency of two to three times daily. The primary dosing principle is the application of the lowest effective dose for the shortest duration necessary to manage symptoms, with the total daily intake never to exceed three tablets.

Contextual Use and Procedural Rules

For proper intake, the tablet must be swallowed whole with liquid and is officially advised to be taken preferably before meals. The tablet must not be divided, crushed, or chewed. Established procedural constraints define a key requirement: this fixed-dose combination must not be co-administered with any other products containing Paracetamol or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Usage in Specific Populations

Official instructions require a dose reduction for older adults and for patients with impaired renal or hepatic function. Additionally, the combination tablet is officially designated as not suitable for use in pediatric patients.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for K-FLAM


️ Evidence for Use in Acute Postoperative Pain

The research base includes short-term randomized controlled trials (RCTs) and systematic reviews that focus on research exploring patient-reported outcomes related to physical discomfort immediately after surgical and dental procedures. These studies typically compare the fixed-dose combination against a placebo or against one of the two active components alone.

Research examined outcomes related to patient-reported outcomes describing perceived discomfort and outcomes capturing phases of heightened symptom activity. Studies report how symptoms evolved in the observed populations, noting patterns related to measured changes in pain intensity scores and the use of supplemental pain medication compared to placebo groups. Evidence is limited for long-term outcomes, and the results apply only to the specific, generally healthy adult populations studied during the acute recovery period.


Evidence for Use in Musculoskeletal Pain and Inflammatory Conditions

The combination was studied for its application in research exploring outcomes related to physical discomfort during conditions characterized by periods of heightened symptoms related to the body's structure, such as temporary flare-ups of low back pain or joint discomfort. The research here includes RCTs and systematic reviews that explore short-term symptom changes over defined time intervals.

Studies report how symptoms evolved in the observed populations, emphasizing outcomes related to episodic or acute changes. Evidence quality varies across studies, and some conclusions rely on synthesizing data from trials of the individual components rather than the fixed combination. This research contributes to understanding symptom patterns but is limited in providing long-term data for chronic management.

--nan

️ Research on the Integrated Management of Pain, Inflammation, and Fever

Research evaluated the fixed combination's role in exploring outcomes related to the symptom cluster of pain, inflammation, and fever. This body of evidence relies on model-based meta-analyses and pharmacological studies that profile the effects of the two components working together. Studies monitored outcomes related to physiological strain or stress and the combined analgesic and antipyretic effect.

What is Still Uncertain About the Research for K-FLAM

Review of the evidence highlights several areas where research is ongoing and certainty remains low. One key limitation is that some evidence relies on trials involving the two components administered separately, which requires inference for the specific oral fixed-dose combination. Furthermore, while the combination has been compared to placebo, the comparative evidence is lacking for how it performs directly against every single-component therapy in all studied conditions.

Key Studies & References

  1. Diclofenac drug information (MedlinePlus)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about K-FLAM (FAQ)


Q: What is the main reason K-FLAM is prescribed?

According to official product information, K-FLAM is indicated for the short-term treatment of acute symptoms. This includes managing pain, inflammation, and swelling associated with conditions such as post-trauma (after injury) or post-surgery. The medicine is also indicated for the management of painful menstrual periods (dysmenorrhoea) and certain painful inflammatory infections.


Q: How is K-FLAM different from over-the-counter anti-inflammatory medicines?

K-FLAM is a combination medicine containing two active ingredients: Diclofenac (a Non-Steroidal Anti-Inflammatory Drug, or NSAID) and Paracetamol. The product is generally categorized as a prescription-only medicine, meaning it requires authorization from a healthcare provider. This classification often distinguishes it from medicines that can be bought directly over-the-counter.


Q: Can K-FLAM be used for short-term swelling?

Official regulatory documents indicate that K-FLAM is used for the short-term treatment of inflammation and swelling. This includes swelling that may occur after acute conditions, such as following a traumatic injury or a surgical procedure.


Q: Are there common side effects for K-FLAM that people notice first?

Studies and official safety information report that the most common adverse effects involve the gastrointestinal system. These include symptoms like nausea, diarrhea, and epigastric pain (stomach pain). This possibility is noted in regulatory information.


Q: What are the serious safety warnings associated with K-FLAM?

Serious warnings for NSAIDs like Diclofenac include an increased risk of serious cardiovascular (CV) thrombotic events (such as heart attack or stroke), and serious gastrointestinal (GI) adverse events (such as bleeding, ulceration, and perforation). The official guidance for this class of medicine includes the principle of using the lowest effective dose for the shortest possible duration.


Q: Is K-FLAM safe to use while breastfeeding?

Official product information states that K-FLAM is contraindicated (not recommended) during lactation or breastfeeding. This restriction is established because the Diclofenac component is described as passing into human milk in small amounts.


Q: Is K-FLAM known to interact with commonly used supplements like multivitamins?

Official prescribing information advises individuals to inform their healthcare provider about any product they are currently taking. This includes not only prescription and non-prescription medicines but also herbal medicines or dietary supplements like multivitamins, as these substances may interact with the medicine.


Q: Are there specific foods or drinks that should be avoided while taking K-FLAM?

The official warning regarding the use of K-FLAM involves alcohol. The concomitant use of alcohol is strongly discouraged, as official information indicates it significantly increases the risk of stomach irritation and severe gastrointestinal bleeding caused by the Diclofenac component. Outside of limiting alcohol, patients can typically eat and drink normally.


Q: Does K-FLAM affect the ability to drive or operate machinery?

Official product information for this combination medicine does not document specific known effects on the ability to drive or use heavy machinery. Official documents suggest individuals monitor their individual response, especially if side effects that could impair concentration occur.


Q: Is it normal to feel a bit drowsy after taking K-FLAM?

While not listed as a common effect for the K-FLAM combination, official information for its Diclofenac component does report instances of drowsiness and dizziness as potential side effects. This possibility suggests that individuals monitor their reaction to the medicine before driving or operating complex machinery.


Q: Can K-FLAM be used to treat migraines or headaches?

Official documents indicate that K-FLAM is indicated for the treatment of headaches and acute migraine attacks. This means that its therapeutic use includes the relief of these types of pain, based on regulatory approval.


Q: How should K-FLAM be stored at home?

The medicine should be stored at room temperature. Regulatory guidance describes that the container should be kept tightly closed, and the product should be stored away from moisture and heat to maintain its stability and effectiveness.


Q: Is K-FLAM only available by prescription?

Yes, this product is generally categorized as a prescription-only medicine. This designation means that it can only be obtained with a valid prescription from a licensed healthcare provider.


Q: What does the label mean by 'use with caution'?

When official documents state that 'caution is indicated,' it means that certain individuals require close medical surveillance (monitoring by a doctor) while taking the medicine. This advice is typically given for special populations, such as older adults, or for patients with underlying conditions, such as gastrointestinal disorders.


Q: Is it possible to be allergic to K-FLAM?

Yes, K-FLAM is contraindicated in patients with a known hypersensitivity or allergy to Paracetamol or any other component in the medicine. Furthermore, it should not be taken by people who have experienced asthma, hives (urticaria), or a sudden runny nose (acute rhinitis) after using aspirin or other NSAIDs.


Q: Does K-FLAM interact with alcohol?

Yes, official warnings describe that taking K-FLAM with alcohol is strongly discouraged. Alcohol can intensify the effects of the Diclofenac component, leading to a significantly increased risk of serious side effects, particularly stomach irritation and gastrointestinal bleeding.


Q: Why is K-FLAM not recommended during the later stages of pregnancy?

The Diclofenac component, like other NSAIDs, is contraindicated during the third trimester of pregnancy. This restriction is based on the risk of causing fetal renal dysfunction (kidney issues) and the potential for premature closure of the fetal ductus arteriosus, which is a blood vessel important for fetal circulation.


Q: Why is K-FLAM classified under a specific drug category?

K-FLAM is classified based on its active ingredients. The Diclofenac component belongs to the drug class known as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This class is defined by its anti-inflammatory, pain-relieving (analgesic), and fever-reducing properties.


Q: Is there evidence about K-FLAM helping with certain types of nerve pain?

Official regulatory information indicates that NSAIDs (like Diclofenac) and Paracetamol are generally not documented as effective for treating neuropathic pain (nerve pain). Other classes of drugs are typically recommended for this specific condition.


Q: Does K-FLAM cause weight gain or loss?

Official safety documents for the Diclofenac component note that weight changes have been occasionally reported as an adverse experience. However, this is not listed as a common or frequent side effect.


Q: Why are people often told to take K-FLAM with food?

While the K-FLAM combination product is typically advised to be taken before meals, other formulations of Diclofenac are sometimes recommended to be taken with food or milk. This common advice is given to help reduce the risk of gastrointestinal upset or irritation.


Q: Are generic versions of K-FLAM available?

K-FLAM itself is a branded combination product, but generic versions of the individual active ingredients, Diclofenac and Paracetamol, are widely available. Regulatory documents refer to the medicine using these generic chemical names.


Advertisements

How should K-FLAM be stored and disposed of?

Storage and Disposal Requirements for K-FLAM

K-FLAM tablets must be stored strictly according to regulatory labeling to maintain quality. The medicine requires storage at temperatures below 30°C and must be kept in a cool, dry place. The tablets require protection from light and moisture.

It is mandatory to store K-FLAM out of the sight and reach of children. The medicine should remain in its original container and be kept tightly closed.

Official Disposal Rules

Unused or expired K-FLAM must not be disposed of in household trash or wastewater. Consult a pharmacist for instructions on proper disposal, which typically involves collection points or approved pharmaceutical waste channels.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of K-FLAM found in:

A-Z Index: